(CAPR) Capricor Therapeutics - Overview
Stock: Deramiocel, Exosome Vaccine, StealthX Platform, CAP-2003
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 215% |
| Relative Tail Risk | -41.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.87 |
| Alpha | 51.43 |
| Character TTM | |
|---|---|
| Beta | 1.471 |
| Beta Downside | 0.775 |
| Drawdowns 3y | |
|---|---|
| Max DD | 79.08% |
| CAGR/Max DD | 1.06 |
Description: CAPR Capricor Therapeutics December 29, 2025
Capricor Therapeutics (NASDAQ: CAPR) is a clinical-stage biotech focused on cell- and exosome-based therapies, primarily targeting Duchenne muscular dystrophy (DMD) and other high-unmet-need conditions in the U.S.
Its lead candidate, **Deramiocel** (allogeneic cardiosphere-derived cells), is in a Phase 3 trial for DMD, enrolling roughly 200 patients across multiple sites; interim data released in Q2 2024 showed a statistically significant slowdown in loss of ambulation versus placebo.
Capricor’s pipeline also includes a preclinical exosome-protein vaccine for SARS-CoV-2, the **StealthX** engineered-exosome platform (Phase 1 for RNA-, protein-, and small-molecule delivery), and the CAP-2003 allogeneic cardiosphere-derived cell-exosome program for DMD.
The company leverages non-exclusive licensing agreements with Johns Hopkins, the University of Rome, and Cedars-Sinai, plus a Cell Line License with Life Technologies, to access patented exosome know-how and expand its therapeutic portfolio.
From a financial standpoint, CAPR reported **$32 million of cash and short-term investments** at the end of FY 2023, giving it an estimated 12-month runway under current burn-rate assumptions, while its market-cap of roughly **$140 million** reflects a price-to-sales multiple of ~12× on the projected $12 million of 2024 revenue from collaboration milestones.
Sector-wide, the global DMD therapy market is projected to exceed **$5 billion by 2028** (CAGR ≈ 13 %), and the exosome-based drug delivery market is expected to grow at **~35 % CAGR** through 2030, providing a favorable macro-environment for Capricor’s technology focus.
For a deeper quantitative view of CAPR’s valuation metrics, you might explore the analytics on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income: -82.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.54 > 0.02 and ΔFCF/TA -12.84 > 1.0 |
| NWC/Revenue: 654.1% < 20% (prev 281.3%; Δ 372.8% < -1%) |
| CFO/TA -0.48 > 3% & CFO -61.0m > Net Income -82.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.59 > 1.5 & < 3 |
| Outstanding Shares: last quarter (45.7m) vs 12m ago 38.16% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 10.15% > 50% (prev 24.99%; Δ -14.84% > 0%) |
| Interest Coverage Ratio: -28.50 > 6 (EBITDA TTM -83.2m / Interest Expense TTM -2.98m) |
Altman Z'' -15.00
| A: 0.58 (Total Current Assets 101.0m - Total Current Liabilities 28.1m) / Total Assets 126.4m |
| B: -2.17 (Retained Earnings -274.7m / Total Assets 126.4m) |
| C: -0.77 (EBIT TTM -85.0m / Avg Total Assets 109.7m) |
| D: -6.43 (Book Value of Equity -273.8m / Total Liabilities 42.6m) |
| Altman-Z'' Score: -15.26 = D |
Beneish M -4.00
| DSRI: 0.30 (Receivables 59.2k/409.7k, Revenue 11.1m/23.2m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 1.13 (AQ_t 0.00 / AQ_t-1 0.00) |
| SGI: 0.48 (Revenue 11.1m / 23.2m) |
| TATA: -0.17 (NI -82.0m - CFO -61.0m) / TA 126.4m) |
| Beneish M-Score: -4.07 (Cap -4..+1) = AAA |
What is the price of CAPR shares?
Over the past week, the price has changed by +12.93%, over one month by -5.40%, over three months by +293.63% and over the past year by +72.51%.
Is CAPR a buy, sell or hold?
- StrongBuy: 5
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CAPR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 50.8 | 105.5% |
| Analysts Target Price | 50.8 | 105.5% |
| ValueRay Target Price | 35 | 41.7% |
CAPR Fundamental Data Overview February 02, 2026
P/B = 14.1986
Revenue TTM = 11.1m USD
EBIT TTM = -85.0m USD
EBITDA TTM = -83.2m USD
Long Term Debt = 14.5m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 120.1k USD (from shortTermDebt, last quarter)
Debt = 14.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -4.97m USD (from netDebt column, last quarter)
Enterprise Value = 1.11b USD (1.19b + Debt 14.5m - CCE 98.6m)
Interest Coverage Ratio = -28.50 (Ebit TTM -85.0m / Interest Expense TTM -2.98m)
EV/FCF = -16.19x (Enterprise Value 1.11b / FCF TTM -68.4m)
FCF Yield = -6.18% (FCF TTM -68.4m / Enterprise Value 1.11b)
FCF Margin = -614.3% (FCF TTM -68.4m / Revenue TTM 11.1m)
Net Margin = -736.6% (Net Income TTM -82.0m / Revenue TTM 11.1m)
Gross Margin = unknown ((Revenue TTM 11.1m - Cost of Revenue TTM 75.9m) / Revenue TTM)
Tobins Q-Ratio = 8.75 (Enterprise Value 1.11b / Total Assets 126.4m)
Interest Expense / Debt = 2856 % (Interest Expense 415.4m / Debt 14.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -67.1m (EBIT -85.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.59 (Total Current Assets 101.0m / Total Current Liabilities 28.1m)
Debt / Equity = 0.17 (Debt 14.5m / totalStockholderEquity, last quarter 83.9m)
Debt / EBITDA = 0.06 (negative EBITDA) (Net Debt -4.97m / EBITDA -83.2m)
Debt / FCF = 0.07 (negative FCF - burning cash) (Net Debt -4.97m / FCF TTM -68.4m)
Total Stockholder Equity = 115.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -74.74% (Net Income -82.0m / Total Assets 126.4m)
RoE = -70.99% (Net Income TTM -82.0m / Total Stockholder Equity 115.5m)
RoCE = -65.35% (EBIT -85.0m / Capital Employed (Equity 115.5m + L.T.Debt 14.5m))
RoIC = -58.12% (negative operating profit) (NOPAT -67.1m / Invested Capital 115.5m)
WACC = 11.20% (E(1.19b)/V(1.21b) * Re(11.34%) + (debt cost/tax rate unavailable))
Discount Rate = 11.34% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 30.66%
Fair Price DCF = unknown (Cash Flow -68.4m)
EPS Correlation: -14.77 | EPS CAGR: 22.47% | SUE: 4.0 | # QB: 1
Revenue Correlation: -28.99 | Revenue CAGR: -83.86% | SUE: -0.15 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.50 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=5
EPS next Year (2026-12-31): EPS=0.15 | Chg30d=+0.000 | Revisions Net=+4 | Growth EPS=+107.0% | Growth Revenue=+21564.7%